




Searching News Database: AML
HSMN NewsFeed - 19 Apr 2021
Curis Receives FDA Orphan Drug Designation for CA-4948 for the Treatment of AML and MDS
Curis Receives FDA Orphan Drug Designation for CA-4948 for the Treatment of AML and MDS
HSMN NewsFeed - 1 Dec 2020
Actinium Appoints Mary Mei Chen, M.D., Ph.D. as Vice President of Clinical Development
Actinium Appoints Mary Mei Chen, M.D., Ph.D. as Vice President of Clinical Development
HSMN NewsFeed - 4 Sep 2020
AbbVie and I-Mab Enter into Global Strategic Partnership for Differentiated Immuno-oncology Therapy
AbbVie and I-Mab Enter into Global Strategic Partnership for Differentiated Immuno-oncology Therapy
HSMN NewsFeed - 7 Aug 2018
Infinity Pharmaceuticals Appoints Samuel Agresta, M.D., M.P.H. as Chief Medical Officer
Infinity Pharmaceuticals Appoints Samuel Agresta, M.D., M.P.H. as Chief Medical Officer
HSMN NewsFeed - 20 Apr 2018
SELLAS Life Sciences Announces Appointment of Gene Mack as Chief Financial Officer & Treasurer
SELLAS Life Sciences Announces Appointment of Gene Mack as Chief Financial Officer & Treasurer
HSMN NewsFeed - 27 Feb 2018
Amgen Receives Positive CHMP Opinion For Delivery System Of Neulasta(R) (pegfilgrastim)
Amgen Receives Positive CHMP Opinion For Delivery System Of Neulasta(R) (pegfilgrastim)
HSMN NewsFeed - 2 Aug 2017
ArcherDX expands blood-based mutation assay portfolio with new myeloid panels
ArcherDX expands blood-based mutation assay portfolio with new myeloid panels
HSMN NewsFeed - 22 Mar 2017
Moleculin Receives Orphan Drug Designation for Annamycin for the Treatment of Acute Myeloid Leukemia
Moleculin Receives Orphan Drug Designation for Annamycin for the Treatment of Acute Myeloid Leukemia
HSMN NewsFeed - 8 Mar 2017
Celyad obtains FDA approval to initiate the NKR-2 CAR T cells THINK trial in the USA
Celyad obtains FDA approval to initiate the NKR-2 CAR T cells THINK trial in the USA
HSMN NewsFeed - 17 Feb 2017
LYNPARZA(TM) (olaparib) Meets Primary Endpoint in Phase III Trial in BRCA-Mutated Metastatic Breast Cancer
LYNPARZA(TM) (olaparib) Meets Primary Endpoint in Phase III Trial in BRCA-Mutated Metastatic Breast Cancer
HSMN NewsFeed - 26 Oct 2016
Actinium Pharmaceuticals Announces New Hires As Supply Chain Organization Expands To Accommodate Growth
Actinium Pharmaceuticals Announces New Hires As Supply Chain Organization Expands To Accommodate Growth
HSMN NewsFeed - 25 Aug 2016
Sunesis Announces Publication in "Drugs" Detailing Molecular and Pharmacologic Properties of Vosaroxin
Sunesis Announces Publication in "Drugs" Detailing Molecular and Pharmacologic Properties of Vosaroxin
HSMN NewsFeed - 4 Apr 2016
BioLineRx's Novel Treatment for Non-Surgical Removal of Skin Lesions Receives CE Mark Approval
BioLineRx's Novel Treatment for Non-Surgical Removal of Skin Lesions Receives CE Mark Approval
HSMN NewsFeed - 25 Jan 2016
BioLineRx Receives Confirmation of Medical Device Classification in Europe for Celiac Treatment
BioLineRx Receives Confirmation of Medical Device Classification in Europe for Celiac Treatment
HSMN NewsFeed - 13 May 2015
Jeng-Dar Yang Ph.D. Joins Actinium Pharmaceuticals as Vice President of Pharmaceutical Development
Jeng-Dar Yang Ph.D. Joins Actinium Pharmaceuticals as Vice President of Pharmaceutical Development
HSMN NewsFeed - 12 Jan 2015
CTI BioPharma Appoints Alan K. Burnett, M.D. As Therapeutic Area Lead, Myeloid Diseases
CTI BioPharma Appoints Alan K. Burnett, M.D. As Therapeutic Area Lead, Myeloid Diseases
HSMN NewsFeed - 10 Feb 2014
Sunesis Appoints Joseph I. DePinto as Chief Commercial Officer, Updates VALOR Timeline to Unblinding of Data
Sunesis Appoints Joseph I. DePinto as Chief Commercial Officer, Updates VALOR Timeline to Unblinding of Data
HSMN NewsFeed - 30 Jan 2014
Stem Cell Therapeutics Announces Appointment of Dr. Calvin R. Stiller as Chairman
Stem Cell Therapeutics Announces Appointment of Dr. Calvin R. Stiller as Chairman
HSMN NewsFeed - 2 Jan 2014
Cell Therapeutics Announces Removal of the Partial Clinical Hold on Tosedostat
Cell Therapeutics Announces Removal of the Partial Clinical Hold on Tosedostat
HSMN NewsFeed - 18 Nov 2013
Actinium Pharmaceuticals Announces Plans For Iomab(TM)-B Phase 3 Pivotal Trial Following Meeting With FDA
Actinium Pharmaceuticals Announces Plans For Iomab(TM)-B Phase 3 Pivotal Trial Following Meeting With FDA
HSMN NewsFeed - 20 Aug 2013
EpiCept Announces Reverse Stock Split and Change of Corporate Name to Immune Pharmaceuticals Inc.
EpiCept Announces Reverse Stock Split and Change of Corporate Name to Immune Pharmaceuticals Inc.
HSMN NewsFeed - 4 Feb 2013
Stem Cell Therapeutics Announces Agreement With Trillium Therapeutics Inc. for Merger
Stem Cell Therapeutics Announces Agreement With Trillium Therapeutics Inc. for Merger
HSMN NewsFeed - 21 Nov 2012
OXiGENE Announces OXi4503 Granted Orphan Designation for Treatment of Acute Myelogenous Leukemia
OXiGENE Announces OXi4503 Granted Orphan Designation for Treatment of Acute Myelogenous Leukemia
HSMN NewsFeed - 16 Nov 2011
Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
HSMN NewsFeed - 24 Oct 2011
Abbott's Genetic Test for Acute Myeloid Leukemia Prognosis Cleared by FDA
Abbott's Genetic Test for Acute Myeloid Leukemia Prognosis Cleared by FDA
HSMN NewsFeed - 15 Dec 2010
EpiCept Announces Initiation by NCI of Phase II Trial with Crolibulin(TM) in Anaplastic Thyroid Cancer
EpiCept Announces Initiation by NCI of Phase II Trial with Crolibulin(TM) in Anaplastic Thyroid Cancer
HSMN NewsFeed - 3 Nov 2010
Coronado Biosciences, Inc. Announces Completion of Financings, Management Changes and Development Update
Coronado Biosciences, Inc. Announces Completion of Financings, Management Changes and Development Update
HSMN NewsFeed - 1 Jul 2010
Cyclacel Pharmaceuticals Announces FDA Orphan Drug Designation for Sapacitabine in Both AML and MDS
Cyclacel Pharmaceuticals Announces FDA Orphan Drug Designation for Sapacitabine in Both AML and MDS
HSMN NewsFeed - 11 Jan 2010
EpiCept Announces Commercial Licensing Agreement for Ceplene(R) with Meda in Europe and Pacific Rim
EpiCept Announces Commercial Licensing Agreement for Ceplene(R) with Meda in Europe and Pacific Rim
HSMN NewsFeed - 19 Jun 2009
Cephalon Provides Clinical Update on Lestaurtinib in Relapsed Acute Myelogenous Leukemia
Cephalon Provides Clinical Update on Lestaurtinib in Relapsed Acute Myelogenous Leukemia
HSMN NewsFeed - 22 Apr 2009
Immunomedics Reports Results That Could Expand Use of Milatuzumab in Cancer Therapy
Immunomedics Reports Results That Could Expand Use of Milatuzumab in Cancer Therapy
HSMN NewsFeed - 21 Aug 2008
VIDAZA(R) Receives Expanded FDA Approval to Include Overall Survival in Higher-Risk MDS
VIDAZA(R) Receives Expanded FDA Approval to Include Overall Survival in Higher-Risk MDS
HSMN NewsFeed - 28 Jul 2008
Celator Pharmaceuticals Raises Series C Financing in Excess of $22.5 Million
Celator Pharmaceuticals Raises Series C Financing in Excess of $22.5 Million
HSMN NewsFeed - 9 Jun 2008
CytRx Corporation Signs Definitive Agreement to Acquire Innovive Pharmaceuticals, Inc.
CytRx Corporation Signs Definitive Agreement to Acquire Innovive Pharmaceuticals, Inc.
HSMN NewsFeed - 3 Jun 2008
Sunesis Pharmaceuticals Focuses Resources on Development of Voreloxin (Formerly SNS-595)
Sunesis Pharmaceuticals Focuses Resources on Development of Voreloxin (Formerly SNS-595)
HSMN NewsFeed - 27 May 2008
Cyclacel's Sapacitabine Receives Orphan Designation for AML & MDS From EU Regulators
Cyclacel's Sapacitabine Receives Orphan Designation for AML & MDS From EU Regulators
HSMN NewsFeed - 27 May 2008
EpiCept Files Re-Examination Documentation for Marketing Authorization of Ceplene(TM) in Europe
EpiCept Files Re-Examination Documentation for Marketing Authorization of Ceplene(TM) in Europe
HSMN NewsFeed - 19 Mar 2008
Genzyme Withdraws Bioenvision's European Filing of Evoltra(R) in Elderly AML Patients
Genzyme Withdraws Bioenvision's European Filing of Evoltra(R) in Elderly AML Patients
HSMN NewsFeed - 27 Feb 2008
EpiCept Announces Non-Binding Opinion by European Regulatory Authority on Ceplene Marketing Application
EpiCept Announces Non-Binding Opinion by European Regulatory Authority on Ceplene Marketing Application
HSMN NewsFeed - 7 Feb 2008
EpiCept Announces Encouraging Results of Phase II Trial for NP-1 Cream in Diabetic Peripheral Neuropathy
EpiCept Announces Encouraging Results of Phase II Trial for NP-1 Cream in Diabetic Peripheral Neuropathy
HSMN NewsFeed - 27 Sep 2007
Genzyme Affirms Purchase Price for Bioenvision at $5.60 Per Outstanding Share
Genzyme Affirms Purchase Price for Bioenvision at $5.60 Per Outstanding Share
HSMN NewsFeed - 20 Sep 2007
European Committee Issues Positive Opinion on Wyeth's TORISEL(TM) for Advanced Renal Cell Carcinoma
European Committee Issues Positive Opinion on Wyeth's TORISEL(TM) for Advanced Renal Cell Carcinoma
HSMN NewsFeed - 17 Sep 2007
Xenomics Announces Agreement with Ipsogen for Diagnostic Assays of Leukemia
Xenomics Announces Agreement with Ipsogen for Diagnostic Assays of Leukemia
HSMN NewsFeed - 11 Jul 2007
Geron Initiates Clinical Trial of Telomerase Cancer Vaccine in Patients with Acute Myelogenous Leukemia
Geron Initiates Clinical Trial of Telomerase Cancer Vaccine in Patients with Acute Myelogenous Leukemia
HSMN NewsFeed - 3 Jun 2007
Exelixis Reports Integrated Data From Phase II Clinical Trials of XL999 at ASCO
Exelixis Reports Integrated Data From Phase II Clinical Trials of XL999 at ASCO
HSMN NewsFeed - 2 Jun 2007
Xanthus Presents Phase 2 Data Showing Xanafide is Associated with Complete Remissions in Secondary AML
Xanthus Presents Phase 2 Data Showing Xanafide is Associated with Complete Remissions in Secondary AML
HSMN NewsFeed - 13 Feb 2007
Seattle Genetics Receives Orphan Drug Designations for its SGN-33 and SGN-35 Programs
Seattle Genetics Receives Orphan Drug Designations for its SGN-33 and SGN-35 Programs
HSMN NewsFeed - 9 Jan 2007
AVI BioPharma and Eleos Announce Cross-License Agreement for p53 Therapeutics
AVI BioPharma and Eleos Announce Cross-License Agreement for p53 Therapeutics
HSMN NewsFeed - 8 Jan 2007
Xanthus Receives Orphan Drug Designation of Xanafide for the Treatment Of AML
Xanthus Receives Orphan Drug Designation of Xanafide for the Treatment Of AML
HSMN NewsFeed - 11 Dec 2006
New Data Validate Vidaza(R) Response Rates in MDS and Report Results in AML
New Data Validate Vidaza(R) Response Rates in MDS and Report Results in AML
HSMN NewsFeed - 27 Nov 2006
Genzyme Begins Phase 2 Pivotal Study of Clolar(R) in Adult Acute Myelogenous Leukemia
Genzyme Begins Phase 2 Pivotal Study of Clolar(R) in Adult Acute Myelogenous Leukemia
HSMN NewsFeed - 1 Nov 2006
EpiCept Announces Successful Validation of Marketing Authorization Application for Ceplene(TM)
EpiCept Announces Successful Validation of Marketing Authorization Application for Ceplene(TM)
HSMN NewsFeed - 31 Oct 2006
Berlex Oncology Evaluating Combination Therapy for Common Form of Non-Hodgkin's Lymphoma
Berlex Oncology Evaluating Combination Therapy for Common Form of Non-Hodgkin's Lymphoma
HSMN NewsFeed - 29 Sep 2006
Xenomics Announces Development of Test for the Genetic Marker for Acute Myeloid Leukemia (AML)
Xenomics Announces Development of Test for the Genetic Marker for Acute Myeloid Leukemia (AML)
HSMN NewsFeed - 26 Sep 2006
Millennium Agrees to Acquire AnorMED, Adding Phase III Oncology Product with Planned Near Term Launch Date
Millennium Agrees to Acquire AnorMED, Adding Phase III Oncology Product with Planned Near Term Launch Date
HSMN NewsFeed - 21 Sep 2006
Latest Data Confirm Benefits of Evoltra(R) in Children with Relapsed/Refractory Acute Leukemia
Latest Data Confirm Benefits of Evoltra(R) in Children with Relapsed/Refractory Acute Leukemia
HSMN NewsFeed - 6 Sep 2006
Genzyme Begins Phase 3 Pivotal Study of Clolar(R) in Adult Acute Myelogenous Leukemia
Genzyme Begins Phase 3 Pivotal Study of Clolar(R) in Adult Acute Myelogenous Leukemia
HSMN NewsFeed - 31 May 2006
Vion Pharmaceuticals Provides Update for Clinical and Preclinical Programs
Vion Pharmaceuticals Provides Update for Clinical and Preclinical Programs
HSMN NewsFeed - 26 May 2006
MGI PHARMA Announces Commercial Availability of Dacogen(TM) (Decitabine) for Injection
MGI PHARMA Announces Commercial Availability of Dacogen(TM) (Decitabine) for Injection
HSMN NewsFeed - 16 May 2006
Bioenvision and Mayne Pharma Announce Marketing and Distribution Agreement for Evoltra(R)
Bioenvision and Mayne Pharma Announce Marketing and Distribution Agreement for Evoltra(R)
HSMN NewsFeed - 11 May 2006
Diatos Announces Acquisition of Specialty Cancer Product DaunoXome(R) from Gilead Sciences
Diatos Announces Acquisition of Specialty Cancer Product DaunoXome(R) from Gilead Sciences
Additional items found! 99

Members Archive contains
99 additional stories matching:
AML
(Password required)
AML
(Password required)